Today, FBR & Co Reiterates “Outperform” Rating for Anavex Life Sciences Corp. (AVXL)

Today, FBR & Co Reiterates “Outperform” Rating for Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Corp. (NASDAQ:AVXL)‘s stock had its “outperform” rating reissued by equities research analysts at FBR & Co in a research note issued to investors on Wednesday. They presently have a $10.00 target price on the stock. FBR & Co’s price objective suggests a potential upside of 178.55% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Maxim Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.

Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.59 on Wednesday. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $14.84. The stock’s 50 day moving average price is $3.13 and its 200 day moving average price is $4.51. The stock’s market capitalization is $128.20 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. Equities research analysts forecast that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Several large investors have recently bought and sold shares of AVXL. American International Group Inc. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter worth $115,000. Nationwide Fund Advisors bought a new position in shares of Anavex Life Sciences Corp. during the second quarter worth $130,000. Rhumbline Advisers bought a new position in shares of Anavex Life Sciences Corp. during the second quarter worth $192,000. Schwab Charles Investment Management Inc. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter worth $313,000. Finally, Teachers Advisors Inc. bought a new position in shares of Anavex Life Sciences Corp. during the second quarter worth $314,000. 10.72% of the stock is owned by institutional investors.

Anavex Life Sciences Corp. Company Profile

Related posts

Leave a Comment